NEW YORK (GenomeWeb) – NanoString said today that life science reagents firm Abcam will provide antibodies for use with its GeoMx Digital Spatial Profiler (DSP) platform, which the company launched this week at the American Association for Cancer Research annual meeting.
Under the agreement, Abcam will create custom panels for the GeoMx DSP platform from its collection of 6,000-plus recombinant monoclonal antibodies, which have been validated for use in fresh frozen and formalin-fixed paraffin-embedded tissue.
The GeoMx DSP platform allows for multiplexed spatial profiling of RNA and proteins."Researchers using our GeoMx DSP platform often want to customize their analysis," Brad Grey, president and CEO of NanoString, said in a statement. "We have partnered with Abcam to facilitate access to their broad portfolio of high quality, validated antibodies to augment our off-the-shelf GeoMx Protein Panels."
"We are excited to be partnering with NanoString to support the GeoMx DSP users' ground-breaking research," John Baker, SVP of product portfolio and innovation at Abcam, said in a statement. "Our recombinant monoclonal antibodies help ensure robust and quantitative spatial protein analysis of even the most challenging samples and may ultimately accelerate vital biomarker discoveries."